Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

M. Ladetto*, F. Zallio, S. Vallet, I. Ricca, A. Cuttica, D. Caracciolo, P. Corradini, M. Astolfi, S. Sametti, F. Volpato, P. Bondesan, U. Vitolo, M. Boccadoro, A. Pileri, A. M. Gianni, C. Tarella

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Journal article

48 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Neuroscience